Although clozaril is entering its 5th year of Food & Drug Administration approved use, less than 20% of those schizophrenic patients who qualify as treatment-resistant have been given clozaril. This Letter to the Editor reports recently released data on death rates of chozaril-treated patients both from agranulocytosis & from suicide. This data clearly shows that a schizophrenic patient is more certain to live to a ripe old age if they are on clozaril.